Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis

Medicinal Research Reviews

Volumn 28, Issue 5, 2008, Pages 688-714

  Ishibashi, Masami ^a   Ohtsuki, Takashi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Curcuma parviflora; Myxomycete; Natural products; TRAIL

Indexed keywords

2 METHOXYESTRADIOL; 3 INDOLEMETHANOL; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ACETYLSALICYLIC ACID; APIGENIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CURCUMIN; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; FLAVANONE; FLAVOPIRIDOL; ISOFLAVONE; LEXATUMUMAB; LONAFARNIB; LUTEOLIN; NORDIHYDROGUAIARETIC ACID; QUERCETIN; RESVERATROL; SILIBININ; SULFORAPHANE; SULINDAC SULFIDE; TAMOXIFEN; THAPSIGARGIN; TIPIFARNIB; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUNICAMYCIN; UNINDEXED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; COLORECTAL CANCER; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; REVIEW; TUMOR CELL;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZ(A)ANTHRACENES; CASPASES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOFLAVONES; NEOPLASMS; PROLINE; PROTEIN KINASES; RECEPTORS, DEATH DOMAIN; SESQUITERPENES; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 50249129735     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20123     Document Type: Review

References (92)

1. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004;432:829-837.
2. Clardy J, Fischbach MA, Walsh C. New antibiotics from bacterial natural products. Nat Biotechnol 2006;24:1541-1550.
3. Newman DJ, Cragg CM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-477.
4. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-1037.
5. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95:777-783.
6. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-3757.
7. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: Present and future challenges. Expert Opin Ther Targets 2007;11:1299-1314.
8. Thorburn A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2007;2:461-465.
9. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-260.
10. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Therapy 2005;12:228-237.
11. Camidge DR. The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer. Clin Lung Cancer 2007;8:413-419.
12. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007;6:1387-1399.
13. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: Mechanisms and clinical implications. Drug Resist Update 2004;7:139-156.
14. Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Yoshiba T, Sakai T, Koyano T, Kam TS, Murata K, Sugahara K, Tsuruda K, Akamatsu N, Tsukasaki K, Masuda M, Takasu N, Kamihira S. Blood. 2006;107:679-688.
15. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Matsui H, Sakai T. Luteolin induces apoptosis via death receptor 5 up-regulation in human malignant tumor cells. Oncogene 2005;24:7180-7189.
16. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 2005;65:7815-7823.
17. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys Res Commun 2005;333:833-838.
18. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC. Curcumin (diferuloylmethane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003;2:95-103.
19. Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 (DR5). Carcinogenesis 2005;26:1905-1913.
20. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004;64:337-346.
21. Jeon KI, Rih JK, Kim HJ, Lee YJ, Cho CH, Goldberg ID, Rosen EM, Bae I. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 2003;544:246-251.
22. Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 2002;62:4180-4185.
23. Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong SW. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003;63:621-626.
24. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-κB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: Correlation with downregulation of NF-κB-responsive genes. Clin Cancer Res 2004;10:3169-3178.
25. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, Yun CO, Choi KS. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and downregulation of c-FLIP and survivin. Cancer Res 2007;67:8274-8784.
26. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007;6:2591-2599.
27. Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4′, 5 tri-hydroxystilbene): Molecular mechanisms and therapeutic potential. J Mol Signal 2007;2:7.
28. Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: Molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal 2007;2:10.
29. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003;63:5390-5400.
30. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149-7155.
31. Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 up-regulation and NF-κB inactivation. Oncogene 2003;22:1653-1662.
32. Meng RD, El-Deiry WS. p53-independent up-regulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001;262:154-169.
33. He Q, Luo X, Huang Y, Sheikh MS. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 2002;21:6032-6040.
34. He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 2002;21:2623-2633.
35. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22:4953-4963.
36. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 up-regulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004;23:2554-2558.
37. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F, Sun SY. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-4988.
38. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Pribluda VS. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003;63:468-475.
39. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735-1743.
40. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors up-regulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004;23:6261-6271.
41. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12- dioxooleana-1,9-dien-28-oate in human lung cancer cells. Cancer Res 2004;64:7570-7578.
42. Zou W, Chen S, Liu X, Yue P, Sporn MB, Khuri FR, Sun SY. c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol Ther 2007 (in press).
43. Wang MJ, Liu S, Liu Y, Zheng D. Actinomycin D enhances TRAIL-induced caspase-dependent and - independent apoptosis in SH-SY5Y neuroblastoma cells. Neurosci Res 2007;59:40-46.
44. Yoo J, Lee YJ. Aspirin enhances TRAIL-mediated apoptosis in hormone refractory prostate cancer cells through survivin downregulation. Mol Pharmacol 2007;72:1586-1592.
45. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 2007;98:1969-1976.
46. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 2007 (in press).
47. Poh TW, Huang S, Hirpara JL, Pervaiz S. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ 2007;14:1813-1825.
48. Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A, Sakai T. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 2007;98:1417-1423.
49. Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, Sun SY. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res 2007;67:4973-4980.
50. Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem 2007;282:18800-18809.
51. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 2005;65:6364-6370.
52. Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ, Choi KS. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 2006;66:1740-1750.
53. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006;66:5867-5874.
54. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471-1474.
55. Ishibashi M. Study on myxomycetes as a new source of bioactive natural products. Yakugaku Zasshi 2007;127:1369-1381.
56. Ishibashi M, Yamaguchi Y, Hirano YJ. Bioactive natural products from nudibranchs. In: Fingerman M, Nagabhushanam R, editors. Biomaterials from aquatic and terrestrial organisms. Enfield: Science Publishers Inc.; 2006. pp 513-535.
57. Li X, Ohtsuki T, Shindo S, Sato M, Koyano T, Preeprame S, Kowithayakorn T, Ishibashi M. Mangiferin identified in a screening study guided by neuraminidase inhibitory activity. Planta Medica 2007;73:1195-1196.
58. Ohtsuki T, Yokosawa E, Koyano T, Preeprame S, Kowithayakorn T, Sakai S, Toida T, Ishibashi M, Quinic acid esters from Pluchea indica with collagenase, MMP-2, and MMP-9 inhibitory activity. Phytother Res 2007 (in press).
59. Ohtsuki T, Sato M, Koyano T, Kowithayakorn T, Kawahara N, Goda Y, Ishibashi M. Steroidal saponins from Calamus insignis and their cell growth and cell cycle inhibitory activities. Bioorg Med Chem 2006;14:659-665.
60. Teramachi F, Koyano T, Kowithayakorn T, Hayashi M, Komiyama K, Ishibashi M. Collagenase inhibitory quinic acid esters from Ipomoea pes-caprae. J Nat Prod 2005;68:794-796.
61. Takahashi M, Koyano T, Kowithayakorn T, Hayashi M, Komiyama K, Ishibashi M. Parviflorene A, a novel cytotoxic unsymmetrical sesquiterpene-dimer constituent from Curcuma parviflora. Tetrahedron Lett 2003;44:2327-2329.
62. Toume K, Takahashi M, Koyano T, Kowithayakorn T, Yamaguchi K, Hayashi M, Komiyama K, Ishibashi M. Parviflorenes B-F, novel cytotoxic unsymmetrical sesquiterpene-dimers with three backbone skeletons from Curcuma parviflora. Tetrahedron 2004;60:10817-10824.
63. Tourne K, Sato M, Koyano T, Kowithayakorn T, Yamori T, Ishibashi M. Cytotoxic dimeric sesquiterpenoids from Curcuma parviflora: Isolation of three new parviflorenes and absolute stereochemistry of parviflorenes A, B, D, F, and G. Tetrahedron 2005;61:6700-6706.
64. Hano Y, Akiyama A, Nomura T. Stereochemistries and CD spectra of two new sesquiterpenoids from the fresh rhizome of cultivated Curcuma sp. in Miyakojima island. Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 1997;39:511-516.
65. Oyarzun ML, Garbarino JA. Sesquiterpenoids from Pilgerodendron uvífera. Phytochemistry 1988;27:1121-1123.
66. Delgado G, del Socoro Olivares M, Cháves MI, Ramíres-Apan T, Linares E, Bye R, Espinosa-García FJ. Antiinflammatory constituents from Heterotheca inuloides. J Nat Prod 2001;64:861-864.
67. Dechary JM, Pradel P. Occurrence of (+)-gossypol in Gossypium species. J Am Oil Chem Soc 1971;48:563-564.
68. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999;59:4042-4049.
69. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
70. Serradell MC, Guasconi L, Cervi L, Chiapello LS, Masih DT. Excretory-secretory products from Fasciola hepatica indiced eosinophil apoptosis by a caspase-dependent mechanism. Vet Immunol Immunopathol 2007;117:197-208.
71. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001;20:2122-2133.
72. Sinicrope FA, Penington RC. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 2005;4:1475-1483.
73. Ohtsuki T, Tamaki M, Toume K, Ishibashi M. A novel sesquiterpenoid dimer parviflorene F induces apoptosis by up-regulating the expression of TRAIL-R2 and a caspase-dependent mechanism. Bioorg Med Chem 2008 (in press).
74. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
75. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
76. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Therapy 2005;12:228-237.
77. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001;507:381-385.
78. Kikuchi H, Ohtsuki T, Koyano T, Kowithayakorn T, Sakai T, Ishibashi M. Brandisianins A-F, isoflavonoids isolated from Millettia brandisiana in a screening program for death-receptor expression enhancement activity. J Nat Prod 2007;70:1910-1914.
79. Hasegawa H, Yamada Y, Harasawa H, Tsuji T, Murata K, Sugahara K, Tsuruda K, Ikeda S, Imaizumi Y, Tomonaga M, Masuda M, Takasu N, Kamihira S. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol 2005;128:253-265.
80. Osaki N, Koyano T, Kowithayakorn T, Hayashi M, Komiyama K, Ishibashi M. Sesquiterpenoids and plasmin-inhibitory flavonoids from Blumea balsamifera. J Nat Prod 2005;68:447-449.
81. Nakatani S, Yamamoto Y, Hayashi M, Komiyama K, Ishibashi M. Cycloanthranilylproline-derived constituents from a Myxomycete Fuligo candida. Chem Pharm Bull 2004;52:368-370.
82. 2 production. Blood 2007;110:1664-1674.
83. Ishibashi M. Isolation of bioactive natural products from myxomycetes. Med Chem 2005; 1:575-590.
84. Ishibashi M. Search for bioactive natural products from unexploited microbial resources. In: Atta-ur-Rahman, editor. Studies in natural products chemistry, Vol. 29. Amsterdam: Elsevier Science; 2003. pp 223-262.
85. Nakata S, Yoshida T, Shiraishi T, Horinaka M, Kouhara J, Wakada M, Sakai T. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 2006;5:1827-1835.
86. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-6083.
87. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-1441.
88. Zeng Y, Wu XX, Fiscella M, Shimada O, Humphreys R, Albert V, Kakehi Y. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006;28:421-430.
89. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Sakai T. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2006;5:945-951.
90. Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A. α-Tocopheryl succinate induced DR4 and DR5 expression by a p53-dependent route: Implication for sensitization of resistant cancer cells to TRAIL apoptosis. FEBS Lett 2006;580:1925-1931.
91. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Dong F, Fang B. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005;4:781-786.
92. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, DeForge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;280:2205-2212.